Abstract Number: 1757 • 2012 ACR/ARHP Annual Meeting
B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura
Background/Purpose: B cell depletion therapy based on rituximab (RTX) is an effective therapy for Rheumatoid Arthritis (RA) and for Thrombotic Thrombocytopenic Purpura (TTP). Serum B…Abstract Number: 1717 • 2012 ACR/ARHP Annual Meeting
Autologous Lipostructure in the Treatment of Fibrotic Perioral Changes in Systemic Sclerosis: A Pilot Study
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by varying degree of fibrosis in skin and other tissues. Therapeutic options for fibrotic changes are very…Abstract Number: 1718 • 2012 ACR/ARHP Annual Meeting
Cost Effectiveness of Nurse-Led Care for People with Rheumatoid Arthritis: A Multicentre RCT
Background/Purpose: Despite the establishment of the innovative rheumatology nurse-led clinics (NLC) in the UK, the evidence of their cost-effectiveness is unknown. This study aimed at…Abstract Number: 1719 • 2012 ACR/ARHP Annual Meeting
What Do Patients Put up with for the Benefit They Get From Methotrexate?
Background/Purpose: As with all effective drugs, Methotrexate (MTX) comes with a range of side effects. Some such as pneumonitis are severe enough to require the…Abstract Number: 1720 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Rheumatoid Arthritis Is Nurse Led Intervention Effective?
Background/Purpose: There is a recognised increase in the incidence of heart disease in patients with rheumatoid arthritis (RA) Surveys of usual practice however frequently show…Abstract Number: 1721 • 2012 ACR/ARHP Annual Meeting
Development of User-Focused Standards of Care for Rheumatoid Arthritis the Www.Eumusc.Net Project – Work Package 5
Background/Purpose: The EUMUSC.net project facilitates cooperation between EU Member States and promotes a comprehensive European strategy to optimise musculoskeletal health.The purpose of Work package 5,…Abstract Number: 1722 • 2012 ACR/ARHP Annual Meeting
Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices
Background/Purpose: For patients with rheumatoid arthritis (RA), making treatment decisions can be overwhelming. The literature describes a sense of ambivalence among patients with chronic diseases…Abstract Number: 1723 • 2012 ACR/ARHP Annual Meeting
The Development of the Rheumatoid Arthritis Patient Priorities in Pharmacological Intervention Outcome Measures
Background/Purpose: Previous research developed a set of 8 priority treatment outcomes generated by patients to complement the professionally developed ACR core set for RA. These…Abstract Number: 1724 • 2012 ACR/ARHP Annual Meeting
Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?
Background/Purpose: There are scarce data suggesting that pandemic influenza vaccination may induce antiphospholipid (APL) autoantibodies in inflammatory rheumatic diseases, particularly in systemic lupus erythematosus patients.…Abstract Number: 1725 • 2012 ACR/ARHP Annual Meeting
ANTI-Factor Xa Antibodies ARE Significantly Increased in Patients with Systemic LUPUS Erythematosus and Antiphospholipid Syndrome
Background/Purpose: Increased levels of antibodies against different serine proteases (SP) have been identified in patients with the Antiphospholipid Syndrome (APS) compared with healthy controls. These…Abstract Number: 1726 • 2012 ACR/ARHP Annual Meeting
Lack of Correlation Between Mannose-Binding Lectin Gene Polymorphisms and the Thickness of the Carotid Artery Intima-Media (IMT) in Primary Antiphspholipid Syndrome
Background/Purpose: Serum mannose-binding lectin (MBL) is a recognition molecule of the lectin pathway of complement with antimicrobial and anti-inflammatory actions. Several polymorphisms have been reported…Abstract Number: 1727 • 2012 ACR/ARHP Annual Meeting
Affinity Purified Antibodies Directed to Domain I of β2GPI Are Pathogenic in a Mouse Model of Thrombosis
Background/Purpose: Circulating IgG antiphospholipid antibodies (aPL) against β2-glycoprotein I (aβ2GPI) are a serological hallmark for diagnosis of the antiphospholipid syndrome (APS). We and other groups…Abstract Number: 1728 • 2012 ACR/ARHP Annual Meeting
Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway
Background/Purpose: Patients with the Antiphospholipid Syndrome (APS) have circulating antiphospholipid antibodies which cause vascular thrombosis (VT) and/or pregnancy morbidity (PM). Previously we have shown that…Abstract Number: 1729 • 2012 ACR/ARHP Annual Meeting
Ribophorin II Is Involved in the Tissue Factor Expression Mediated by Phosphatidylserine-Dependent Antiprothrombin Antibody On Monocytes
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thrombosis and the presence of antiphospholipid antibodies (aPL). Tissue factor (TF), the major initiator of the extrinsic coagulation…Abstract Number: 1730 • 2012 ACR/ARHP Annual Meeting
Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus
Background/Purpose: Phosphatidylethanolamine, a zwitterionic phospholipid, is a major component of the cell plasma membrane. Phospatidylethanolamine exerts both anticoagulant and procoagulant activities in different conditions. The…